5 Stocks in the News…
Things like news releases or earnings announcements can be important triggers to look for… And we found 5 stocks that appear to be in an excellent position to deliver high-probability trading opportunities in the days and weeks ahead.

Click Here to Get ALL 5 Stocks.
Sandra Calvin net worth and biography

Sandra Calvin Biography and Net Worth

Sandra E. Poole is Chief Operating Officer of Advantagene, Inc. She is also on the board of ViaCyte, Inc. and Travere Therapeutics, Inc.

In her past career Ms. Poole was Chief Operating Officer for LogicBio Therapeutics, Inc., EVP-Technical Operations & Commercial Development at ImmunoGen, Inc., Managing Director at S. Poole Consulting LLC and Senior Vice President-Biologics Manufacturing at Genzyme Corp.

Ms. Poole received a graduate degree and an undergraduate degree from The University of Waterloo.

What is Sandra Calvin's net worth?

The estimated net worth of Sandra Calvin is at least $702,130.82 as of September 13th, 2022. Ms. Calvin owns 35,933 shares of Travere Therapeutics stock worth more than $702,131 as of December 2nd. This net worth approximation does not reflect any other assets that Ms. Calvin may own. Learn More about Sandra Calvin's net worth.

How old is Sandra Calvin?

Ms. Calvin is currently 57 years old. There are 6 older executives and no younger executives at Travere Therapeutics. The oldest executive at Travere Therapeutics is Dr. William E. Rote Ph.D., Sr. VP and Head of R&D, who is 59 years old. Learn More on Sandra Calvin's age.

How do I contact Sandra Calvin?

The corporate mailing address for Ms. Calvin and other Travere Therapeutics executives is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. Travere Therapeutics can also be reached via phone at (888) 969-7879 and via email at [email protected] Learn More on Sandra Calvin's contact information.

Has Sandra Calvin been buying or selling shares of Travere Therapeutics?

Sandra Calvin has not been actively trading shares of Travere Therapeutics during the last ninety days. Most recently, Sandra Calvin sold 349 shares of the business's stock in a transaction on Tuesday, September 13th. The shares were sold at an average price of $28.00, for a transaction totalling $9,772.00. Following the completion of the sale, the chief accounting officer now directly owns 35,933 shares of the company's stock, valued at $1,006,124. Learn More on Sandra Calvin's trading history.

Who are Travere Therapeutics' active insiders?

Travere Therapeutics' insider roster includes Steve Aselage (Director), Sandra Calvin (CAO), Laura Clague (CFO), Eric Dube (CEO), Peter Heerma (Insider), Elizabeth Reed (SVP), Noah Rosenberg (Insider), and William Rote (SVP). Learn More on Travere Therapeutics' active insiders.

Are insiders buying or selling shares of Travere Therapeutics?

During the last year, insiders at the sold shares 18 times. They sold a total of 48,191 shares worth more than $1,267,693.04. The most recent insider tranaction occured on October, 4th when insider Peter Heerma sold 3,042 shares worth more than $78,118.56. Insiders at Travere Therapeutics own 4.7 % of the company. Learn More about insider trades at Travere Therapeutics.

Information on this page was last updated on 10/4/2022.

Sandra Calvin Insider Trading History at Travere Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/13/2022Sell349$28.00$9,772.0035,933View SEC Filing Icon  
5/10/2022Sell436$21.51$9,378.3636,178View SEC Filing Icon  
1/31/2022Sell798$26.51$21,154.98View SEC Filing Icon  
1/24/2022Sell934$24.58$22,957.72View SEC Filing Icon  
See Full Table

Sandra Calvin Buying and Selling Activity at Travere Therapeutics

This chart shows Sandra Calvin's buying and selling at Travere Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Travere Therapeutics Company Overview

Travere Therapeutics logo
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $19.54
Low: $19.52
High: $20.54

50 Day Range

MA: $22.15
Low: $18.99
High: $26.14

2 Week Range

Now: $19.54
Low: $18.70
High: $31.65


586,032 shs

Average Volume

756,317 shs

Market Capitalization

$1.25 billion

P/E Ratio


Dividend Yield



5 Stocks in the News…
Things like news releases or earnings announcements can be important triggers to look for… And we found 5 stocks that appear to be in an excellent position to deliver high-probability trading opportunities in the days and weeks ahead.

Click Here to Get ALL 5 Stocks.